R&D
LEADING INNOVATION

Scroll down to see more

Tri-Pillar Model

Leveraging our know-how and R&D approach, we have developed a robust clinical and pre-clinical pipeline through a combination of internally discovered and in-licensed products.

 

- Internal Discovery

- Business Development

- Translational Research

Our Strengths
AKT inhibitor LAE002 in registrational clinical trials with potentially better clinical efficacy and favorable safety profile

LAE001 exhibits favorable efficacy profile

 for prostate cancer

Profound understanding 

into fundamental

disease biology and clinical practice

 

Highly integrated global operation 

that well-positions us to capture international business opportunities

 

Seasoned and top-tier management team

 
Therapeutic Areas

Our portfolio now covers oncology, liver disease and rare diseases.

  1. Oncology
    ovarian cancer, prostate cancer, breast cancer, PD-1/PD-L1 resistant solid tumors
  2. Liver Fibrosis
  3. Rare Diseases
    Hereditary hemorrhagic telangiectasia, Proteus Syndrome
Therapeutic Areas

Our portfolio now covers oncology, liver disease and rare diseases.

  1. Oncology
    ovarian cancer, prostate cancer, breast cancer, PD-1/PD-L1 resistant solid tumors
  2. Liver Fibrosis
  3. Rare Diseases
    Hereditary hemorrhagic telangiectasia, Proteus Syndrome
Core Products
  1. LAE002
    LAE002 is an ATP competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. MORE
  2. LAE001
    LAE001 is an androgen synthesis inhibitor that inhibits both CYP17A1 and CYP11B2 for the treatment of prostate cancer.MORE
Pipeline

Drug Candidate

Target Mechanism

Indications

Lead
Discovery

Proof of
Mechanism

CMC IND Enabling

Phase I

Phase II

Commercial Rights

Licensor╱Partner

Cancer

  • AKT
    + Chemotherapy
  • AKT + CYP17A
  • AKT + PD-1
    +Chemotherapy
  • AKT + PD-L1
    +chemotherapy
  • AKT + ER
  • PROC (second- to sixth-line treatment)
  • mCRPC following SOC Treatment (second- to fourth-line treatment)
  • PD-1/PD-LI Resistant Solid Tumors
  • TNBC (second- to third-line treatment)
  • Locally Advanced or Metastatic HR+/HER2-Breast Cancer (second- to third-line treatment)
  • MRCT (U.S. and China) | Pivotal

  • MRCT (U.S. and South Korea)

  • MRCT (U.S. and China)

  • CYP17A/CYP11B2
  • mHSPC (first-line treatment)
  • ActRIIA
  • Cancer
  • NK/T regulator
  • Cancer
  • NK/Ø regulator
  • Cancer
  • NK/T regulator
  • Cancer
  • NK/T regulator
  • Cancer
  • TAA
  • Cancer
  • Synthetic lethality
  • Cancer
  • Synthetic lethality
  • Cancer

Liver Fibrosis

  • aHSC depletion
  • Liver Fibrosis
  • aHSC depletion
  • Liver Fibrosis
  • Conditional TGFß blocker
  • Liver Fibrosis

Rare Disease

  • AKT
  • HHT/Proteus Syndrome
Core Product
Internally Discovered
Global Rights Exclusively Licensed

Glossary & abbreviations

PROC: platinum-resistant ovarian cancer         mCPRC: metastatic castration-resistant prostate cancer         mHSPC: metastatic hormone-sensitive prostate cancer         ER: estrogen receptor         TNBC: triple negative breast cancer         HHT: hereditary hemorrhagic telangiectasia


As of March 13, 2023

Pipeline
Core Product
Internally Discovered
Global Rights Exclusively Licensed

(1) Some indication(s) may not require a Phase II clinical trial prior to beginning pivotal Phase II or III clinical trials.

(2) Phase II registration-directed pivotal trial.

(3) The trial is a MRCT covering clinical sites in the U.S. and South Korea. We also plan to include the clinical site in China in the future.

(4) Current clinical trial(s) conducted only in China, but will be extended into MRCT(s) in pivotal trial(s).

(5) LAE003 has been conducted in several Phase I, Phase II clinical trials in various cancer indications prior to our in-licensing. We plan to repurpose the drug for rare disease indications with partners.


Glossary & abbreviations

PROC: platinum-resistant ovarian cancer mCRPC: metastatic castration-resistant prostate cancer mBC: metastatic breast cancer TNBC: triple negative breast cancer HHT: hereditary hemorrhagic telangiectasia ET: endocrine therapy AI: aromatase inhibitors


As of May 31, 2022

Clinical Trials
Conditions Interventions Study Title Status
Solid Tumor
TNBC Triple-Negative Breast Cancer

Combination

Product

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

More information
Recruiting
Platinum-resistant Ovarian Cancer

Drug: Paclitaxel

Drug: Afuresertib

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

More information
Recruiting
Solid Tumor
NSCLC
Cervical Cancer
Endometrial Cancer
Esophageal Cancer
Gastric and Gastroesophageal Junction Adenocarcinoma

Drug: Afuresertib

Drug:Nab paclitaxel

Drug: Docetaxel

Drug: Sintilimab

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

More information
Recruiting
Metastatic Castration-resistant Prostate Cancer

Drug: Phase I and Phase II: LAE001/prednisone + afuresertib

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

More information
Active,
not recruiting
Breast Cancer

Drug: Afuresertib

Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer

More information
Recruiting
Meet Our Scientists
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin